Abstract Optineurin (OPTN) is a multifunctional protein involved in vesicular trafficking, signal transduction and gene expression. OPTN mutations were described in eight Japanese patients with familial and sporadic amyotrophic lateral sclerosis (FALS, SALS). OPTN-positive inclusions co-localising with TDP-43 were described in SALS and in FALS with SOD-1 mutations, potentially linking two pathologically distinct pathways of motor neuron degeneration. We have explored the abundance of OPTN inclusions using a range of antibodies in postmortem tissues from 138 cases and controls including sporadic and familial ALS, frontotemporal lobar degeneration (FTLD) and a wide range of neurodegenerative proteinopathies. OPTN-positive inclusions were uncommon and detected in only 11/32 (34%) of TDP-43-positive SALS spinal cord and 5/15 (33%) of FTLD-TDP. Western blot of lysates from FTLD-TDP frontal cortex and TDP-43-positive SALS spinal cord revealed decreased levels of OPTN protein compared to controls (p \ 0.05), however, this correlated with decreased neuronal numbers in the brain. Large OPTN inclusions were not detected in FALS with SOD-1 and FUS mutation, respectively, or in FTLD-FUS cases. OPTN-positive inclusions were identified in a few Alzheimer's disease (AD) cases but did not co-localise with tau and TDP-43. Occasional striatal neurons contained granular cytoplasmic OPTN immunopositivity in Huntington's disease (HD) but were absent in spinocerebellar ataxia type 3. No OPTN inclusions were detected in FTLD-tau and a-synucleinopathy. We conclude that OPTN inclusions are relatively rare and largely restricted to a minority of TDP-43 positive ALS and FTLD-TDP cases. Our results do not support the proposition that OPTN inclusions play a central role in the pathogenesis of ALS, FTLD or any other neurodegenerative disorder.
Introduction
Optineurin (OPTN) is a ubiquitous 67 kDa cytoplasmic protein with high expression levels in the brain, retina and skeletal muscle [6, 12, 13, 22] . It is an important regulator of the NF-jB signal transduction pathway [28] , membrane trafficking and exocytosis [25] , interacts with transcription factors [18] and binds to glutamate receptors [1, 2] . Rare missense mutations in the OPTN gene have previously been described in hereditary primary open angle glaucoma (POAG) [21] and linked to Paget's disease of the bone [5] . In a recent study employing homozygosity mapping in consanguineous Japanese kindreds with amyotrophic lateral sclerosis (ALS) a common region was identified on chromosome 10. Sequencing of OPTN revealed an exon 5 deletion in two siblings from consanguineous kindred. A homozygous point mutation at c.1502 C[T (Q389X) was detected in one affected individual from two unrelated families, and a missense mutation c.1743 A[G (E478G) was detected in four affected individuals from two unrelated families [16] . The Q398X and E478G mutations were not detected in 781 controls and previously published cohorts (2,803 glaucoma cases and 2,340 controls) [16] . This discovery adds OPTN to the list of genes known to harbour mutations associated with ALS: SOD-1, ANG, TARDBP, FUS and VAPB [8, 19, 24, 27, 30] .
Immunohistochemical studies on a single familial ALS (FALS) case with the E478G OPTN mutation revealed intracytoplasmic neuronal inclusions, which labelled with anti-OPTN antibodies, in spinal cord anterior horn motor neurons. An increase in diffuse cytoplasmic granular labelling was also noted. Sporadic ALS and FALS with SOD-1 mutation also displayed these inclusions, and an increase in diffuse cytoplasmic immunopositivity. In control case anterior horn motor neurons, the absence of inclusions and low levels of cytoplasmic OPTN labelling were reported [16] .
We sought to explore the distribution and biochemical profile of OPTN protein in familial and sporadic ALS cases using immunohistochemistry and western blotting. We also explored OPTN staining in a wide range of neurodegenerative proteinopathies with hallmark TDP-43, FUS/TLS, hyperphosphorylated tau, a-synuclein and polyglutamine inclusions.
Materials and methods

Brain tissue collection and neuropathological assessment
Brain and spinal cord tissues in 10% formalin-fixed, paraffin-embedded tissue blocks were available from the Medical Research Council (MRC) London Neurodegenerative Diseases Brain Bank (Institute of Psychiatry, King's College London, UK). Consent for autopsy, neuropathological assessment and research were obtained from all subjects in accordance with local and national Research Ethics Committee approved donation. Block taking for histological and immunohistochemical studies and neuropathological assessment for neurodegenerative diseases and control cases was performed in accordance with institutional guidelines as described previously [15] .
Case selection and neuropathological characterisation of postmortem brain samples The ALS cases were diagnosed and classified clinically according to consensus criteria [3] . The examined cases (Table S1 ) included: 32 cases of SALS, 2 FALS with FUS mutations, 4 FALS with SOD-1 mutation, 6 frontotemporal lobar degeneration (FTLD) with TDP-43 positive inclusions (FTLD-TDP), 9 FTLD-TDP with co-existing ALS, 10 FTLD-tau (4 Pick's disease (PiD), 5 progressive supranuclear palsy (PSP), 5 corticobasal degeneration (CBD), 1 FTLD with MAPT mutations), 3 FTLD-FUS, 10 Alzheimer's disease (AD), 3 dementia with Lewy bodies (DLB), 5 Huntington's disease (HD), 2 spinocerebellar ataxia type 3 (SCA3; Machado-Joseph disease) (SCA), and 10 controls (defined as no history of neurological symptoms based on satisfactory medical records and no neuropathological features of brain disease). Tissue pH was within an acceptable range of 6.0-7.3 [11] in all cases tested (those where frozen tissue was available).
The demographic details of patients and controls are summarised in Table S1 . Neuropathological assessment and disease classification was performed by consultant neuropathologists according to guidelines specified by the BrainNet Europe Consortium and recent publications [4, 14, 15] . The possible association between OPTN pathology and disease phenotype (age, sex, age and site of onset, duration of disease) as well as tissue factors (postmortem delay and tissue pH) were analysed by MannWhitney statistical test. Intensity levels of OPTN immunostaining were assessed according to a semiquantitative scale (0 = none, 1 = mild, 2 = moderate, 3 = intense) and data were analysed by Kruskal-Wallis statistical test for non-parametric data.
Tissue microarray (TMA)
TMAs from temporal lobe neocortex from 11 ALS, 15 DLB and 11 control cases (Table S2) , respectively, were prepared and analysed by OPTN immunohistochemistry using antibodies with reasonably good staining qualities based on previous testing [OPTN-C and OPTN-I (Cayman), HPA 3360 (Sigma) and OPTN (Bethyl)].
Brain region selection
The following disease-relevant neuroanatomical regions were analysed: For ALS, FTLD-TDP, FTLD-TDP with ALS, AD, PiD and DLB cases, temporal lobe containing hippocampus and spinal cord (cervical and, when available, thoracic segments); in PSP and CBD midbrain with substantia nigra; in HD the caudate nucleus and striatum; and in SCA the cerebellum. Sections from the temporal lobe containing neocortex and hippocampus, spinal cord and midbrain were examined from control cases.
Histological staining, immunohistochemistry and antibodies
The tissue specimens were sampled, fixed and further processed for histological staining and immunohistochemistry (IHC) as described previously [15] . In brief, sections of 7 lm thickness were cut from the formalinfixed paraffin-embedded (FFPE) tissue blocks, deparaffinised in xylene, endogenous peroxidase blocked by H 2 Table 1) . Sections were counterstained with haematoxylin and immunohistochemistry analysed using a Leica microscope (Leica, Wetzlar, Germany).
Double immunoflourescence labelling
7 lm sections were cut from formalin-fixed, paraffinembedded brain tissue blocks and mounted on Superfrost slides (Solmedia, UK). Sections were deparaffinised in xylene and dehydrated in alcohol. Extended citrate pretreatment was carried out before sections were blocked using normal goat serum (30 min incubation). Primary antibodies were applied and sections incubated at 37°C for 1 h. After washing in PBS secondary antibodies were applied for 45 min [Alexa Fluor goat anti-mouse 488 and goat anti-rabbit 568 (Invitrogen, UK)]. Autofluorescence was quenched using Sudan Black (10 min) followed by numerous washes in PBS. Sections were mounted using Vectashield hard set with DAPI (Vector Labs, UK) and visualised using a fluorescent microscope (Zeiss Axiovert S 100, Göttingen, Germany). A quantitative analysis has been performed on OPTN and pTDP-43 double-stained, IFlabelled sections. A total of 550 cells were viewed over several fields and cases and the numbers and percentages of single and double immunolabelled cells were determined.
Biochemistry (Western blotting)
Fresh-frozen postmortem medial temporal lobe cortical brain tissue was obtained from 10 FTLD-TDP patients (4 females and 6 males; mean ± SD age 62.0 ± 10.57 years; mean ± SD postmortem delay 17.97 ± 11.73 h), 12 AD (5 females and 7 males; mean ± SD age 79.75 ± 8.54 years; mean ± SD postmortem delay 15.5 h ± 10.08 h), 6 FTLD-tau (2 females and 4 males; mean ± SD age 59.33 ± 10.35 years; mean ± SD postmortem delay 34.0 ± 16.62 h), and 12 (age, sex, PMI and pH matched) normal controls (6 females and 6 males; mean ± SD age 66.0 ± 10.79 years; mean ± SD postmortem delay 24.63 ± 7.55 h) (Table S3) .
Spinal cord samples were obtained from 10 SALS patients (6 females and 4 males; mean ± SD age 64.6 ± 10.2 years; mean ± SD postmortem delay 32.6 ± 20.3 h) and 10 (age, sex, PMI and pH matched) normal controls (3 females and 7 males; mean ± SD age 70.5 ± 17.3 years; mean ± SD postmortem delay 45.5 ± 24.4 h) (Table S4 ) by means of microdissection of the anterior horn from tissue sections slowly warmed up on ice to a temperature around 0°C to allow dissection of the region of interest. Controls were defined as subjects with no clinical history and no neuropathological evidence of a neurodegenerative condition. Cases with good overall tissue preservation (acceptable pH range, low PMD) were selected. The controls were matched regarding age, sex, and tissue preservation markers. The tissue was homogenized in 10 v/w of high-salt buffer (100 mM 2-(N-morpholino) ethane sulphonic acid (MES) (pH 7.4), 0.5 mM MgCl2, 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), 1 M NaCl, 50 mM imidazole, protease inhibitor cocktail (Roche, Basel, Switzerland). The homogenate was mixed with 29 SDS-PAGE loading buffer and boiled for 10 min. Samples were centrifuged for 20 min at 13,000 rpm and 4°C. Equal volumes of samples were loaded on 26-well NuPAGE Novex 10% Bis-Tris pre-cast gels (Invitrogen, UK) and the membranes were blocked with 10% non-fat dry milk for at least 1 h and incubated with primary antibodies overnight at 4°C. After serial washes with 1% Tween-20 and TBS (TBST), the membranes were incubated with appropriate fluorescent secondary antibody; followed by washes in TBS. Membranes were developed using Odyssey Infrared Imaging System (Li-cor Biosciences). Membranes were probed for OPTN (HPA3360 SigmaAldrich, St Louis, MO, USA), b-3 tubulin (Abcam Ltd, UK) as a neuronal marker and Histone 3 (H3) (Sigma-Aldrich, St Louis, MO, USA) as a loading control general cell marker. Quantification analysis was performed using Odyssey software and OPTN and b-3 tubulin levels were normalized with H3 levels subsequently analysed using GraphPad Prism version 5.03 for Windows (GraphPad Software, San Diego, CA, USA). Statistical significance was estimated by t test or ANOVA Post Hoc Bonferroni test using SPSS 15.0 software (SPSS Inc, Chicago, USA). Correlations between decrease in OPTN levels and decrease of neurons were analysed using Pearson's correlation method in GraphPad Prism. Control brain samples were used in the two Western blotting experiments for comparison with AD, FTLD-tau and FTLD-TDP, respectively, and were also included in the correlation analysis.
Results
OPTN immunohistochemistry in ALS, FTLD-TDP with ALS, and FTLD-TDP
We tested five different OPTN antibodies for IHC and immunofluorescence (IF). The highest specificity and sensitivity to detect inclusions was obtained using a rabbit polyclonal antibody directed to full length human OPTN (Sigma HPA 3360), followed by OPTN-C and OPTN-I (Cayman) as used by Maruyama and colleagues [16] . Using these three antibodies we were able to confirm the presence of round (Fig. 1b, c) and skein-like (Fig. 1e, f ) OPTN-immunopositive inclusions in spinal cord motor neurons in SALS patients as previously described [16] . Controls showed diffuse and usually weak cytoplasmic neuronal labelling and no inclusions were detected (Fig. 1a) . Cytoplasmic inclusions were seen in the spinal cord in 34% of SALS cases (in 11 out of 32). In OPTNpositive cases only a minority of motor neurons contained inclusions which were accompanied by a reduction of diffuse cytoplasmic OPTN labelling (Fig. 1e, f) . Occasional motor neurons had perinuclear granular OPTN staining (Fig. 1f) . Rare cytoplasmic inclusions and cell process positivity were detected in astroglia in the anterior horn (Fig. 1f) . Although all SALS cases had abundant TDP-43 pathology, the majority of TDP-43 inclusions were negative for OPTN which contrasts to previously reported observations [16] . FALS with SOD1 mutation cases were consistently negative with all OPTN antibodies and coarse granular positivity was seen within the cytoplasm of spinal cord motor neurons (Fig. 1d) . However, in the majority of FALS with SOD-1 mutation the inclusions do not show SOD1 immunoreactivity either [26] . There were no OPTN inclusions detected in spinal cord and brain in FALS with FUS mutation cases or the brain of FTLD-FUS cases.
Neuronal and glial OPTN immunoreactive cytoplasmic inclusions and dystrophic neurites (Fig. 2) were noted in the brains of 33% (5/15) of FTLD-TDP and FTLD-TDP with ALS cases. The granule cells of the hippocampal dentate fascia had occasional small paranuclear inclusions (Fig. 2c) . Pyramidal neurons with granular cytoplasmic aggregates (possibly 'preinclusions') are noted (Fig. 2a,  inset ). Double-labelling immunofluorescence with OPTN and pTDP-43 antibodies revealed only occasional colocalisation (Fig. 3b) ; and the majority of TDP-43 inclusions did not co-localise with OPTN (Fig. 3a) . Aside from the inclusions, there were alterations in the intensity of cytoplasmic neuronal OPTN labelling in controls versus FTLD-TDP and SALS. This was best noted with the OPTN-C and OPTN-I antibodies (Fig. S1) . Using a semi-quantitative scale to rate the intensity of staining (0 = none, 1 = mild, 2 = moderate, 3 = intense) SALS cases showed an average intensity of 1.2 ± 0.1 (SEM) and FTLD-TDP of 1.1 ± 0.2 compared to 1.4 ± 0.2 in the controls. FALS with SOD-1 mutation showed a higher intensity with an average of 2.2 ± 0.4, and PiD cases showed the highest of all examined tauopathies, with an average score of 2.8 ± 0.3 which was, however, not significantly higher than that of the control cases. Intensity levels were analysed with Kruskal-Wallis statistical test for non-parametric data. This showed no significant difference between any of the groups (either in standard size tissue sections or in TMA). There was no statistically significant association between the presence of OPTN inclusions in the spinal cord and/or brain and clinical phenotype, disease duration, demographic variable, (Table S5) .
OPTN immunohistochemistry in other neurodegenerative disorders
Occasional AD cases revealed OPTN-positive neuronal and glial cytoplasmic inclusions in areas severely affected by AD-type tau pathology (hippocampus and adjacent temporal lobe neocortex) (Fig. S2a) . The OPTN positivity was different from the pattern of pTDP-43 labelling we have observed in a 44% (4/9) of AD cases. Double-labelling immunofluorescence experiments revealed no evidence of co-localisation of the rare OPTN inclusions with the more frequent tau inclusions (Fig. S2b) . There was no co-localisation of OPTN and pTDP-43 in AD cases with coexisting TDP-43 pathology (44% of AD cases in our series) (Fig.  S2c) . In HD there was increased granular, predominantly perinuclear, cytoplasmic labelling (Fig. S3) ; however, there was no evidence of OPTN labelling of intranuclear inclusions. There was no abnormal staining or inclusions detected in the brains of patients with FTLD-FUS, FTLD-tau (PiD, PSP, CBD, FTLD with MAPT mutation), DLB, and SCA.
Tissue microarray (TMA)
Using the TMA slides, where tissue cores from each case are mounted onto the same slide (thereby reducing experimental variation caused by subtle differences in antibody exposure, humidity, temperature, etc.) a difference in intensity of staining was observed between ALS cases and controls. With the OPTN-C antibody ALS had an average staining intensity of 2.9 ± 0.1 (SEM) and controls of 2.7 ± 0.1. With the Sigma HPA 3360 antibody the effect was more pronounced with ALS showing an average intensity of 0.96 ± 0.2 compared to 0.57 ± 0.1 in the controls (although neither reached statistical significance); however, due to the stronger background labelling of the neuropil, HPA 3360 antibody appears less reliable to assess cytoplasmic labelling as compared to OPTN-C and the same pattern was noted in the brains of FTLD-TDP with ALS versus controls (Fig. S1 ). Of note, both antibodies showed a reduction in immunoreactivity in cases that had been stored in formalin for many years before FFPE block taking.
Biochemistry (Western blotting)
In order to investigate the levels of OPTN in patient tissues we microdissected the anterior horn from SALS spinal cord and FTLD-TDP, AD and FTLD-tau temporal lobe cortex and controls, probed the protein lysate by western blotting and quantification was performed using Odyssey software. A 36% reduction in OPTN levels was detected in ALS spinal cord compared to controls (t test, p \ 0.001) (Fig. 4a, d ). b-3 tubulin levels were reduced 26%, however, with no statistical significance (t test, p = 0.11). Levels of OPTN were reduced 55% in brain of FTLD-TDP patients (t test, p = 0.004) followed by a reduction of 55% of b-3 tubulin (t test, p = 0.002) (Fig. 4b, d ). One-way ANOVA showed significant difference in the levels of OPTN between controls, AD and FTLD-tau (p \ 0.05). Post Hoc Bonferroni test showed that while AD did not differ significantly from controls (p = 0.11), there was a significant difference between levels of OPTN in FTLD-tau patients and age-matched controls p \ 0.05. Post Hoc Bonferroni tests showed a significant difference in b-3 tubulin levels comparing controls and AD (p \ 0.0001) and FTLD-tau (p \ 0.001) (Fig. 4c, d ). Correlation analysis was performed to investigate further if levels of OPTN correlate with levels of b-3 tubulin. We found a significant correlation between decrease of OPTN levels in the brain of patients with FTLD-TDP (r = 0.98, p \ 0.0001), AD (r = 0.82, p = 0.001) and decrease of b-3 tubulin neuronal marker (Fig. S4b, c) . No obvious correlation between decrease of OPTN levels and b-3 tubulin was observed in FTLD-tau (r = 0.54, p = 0.26) and spinal cord of ALS patients (r = 0.40, p = 0.25) (Fig. S4d, a) .
Discussion
After careful optimisation of a range of anti-OPTN antibodies we were able to detect skein-like and round inclusions in a minority of SALS and FTLD-TDP, FTLD-TDP with ALS spinal cord and brain samples as previously reported (Figs. 1, 2) . OPTN immmunopositive inclusions, however, rarely co-localised with pTDP-43 (Fig. 3) and were absent in ALS with SOD-1 and FUS mutation, respectively, which challenges the proposition that OPTN plays a role in the broad pathogenesis of ALS of Maruyama et al. [16] . b-amyloid, hyperphosphorylated tau, a-synuclein and polyglutamine. OPTN inclusions were rarely noted in the hippocampus of some AD cases (often affected by double pathology) and cytoplasmic neuronal aggregates in the striatum of HD cases (but no intranuclear inclusions characteristic of HD). Further studies are required to clarify the true incidence and significance of these findings.
Having tested a range of OPTN antibodies (Table 1) , a rabbit polyclonal antibody (Sigma HPA 3360) proved to be the most reliable in terms of specificity and sensitivity for IHC analysis with DAB as the chromogen. This antibody recognizes a 144 amino acid long sequence close to the N terminus of the molecule with a lower concentration than any of the other tested antibodies (Table 1) . Furthermore, this antibody gave a reasonably good signal (although not as good as with the antibody from Bethyl) when visualized with a fluorescent dye. We also detected inclusions with antibodies used by Maruyama and colleagues [16] (OPTN-I and OPTN-C) thereby confirming their findings; these antibodies were also sensitive enough to label the diffuse and granular cytoplasmic positivity (Fig. S1 ). We were able to identify increased neuronal and glial labelling in a few AD cases (Fig. S2) . OPTN also binds to wild-type and mutant huntingtin [7] , and we were able to identify coarse granular OPTN staining in the striatal neurons in HD cases but no labelling of intranuclear inclusions (Fig. S3) . To elaborate on the significance of the observations in AD and HD further work is needed beyond the scope of this study.
Our semiquantitative IHC analysis revealed no significant difference in neuronal OPTN cytoplasmic staining intensity in TDP-43 positive SALS and FTLD-TDP. However, a modest but non-significant increase was noted in several neurodegenerative diseases, including tauopathies. Our semiquantitative IHC data suggest that a robust increase in cytoplasmic OPTN immunoexpression is not a feature in primary TDP-43 proteinopathies and other neurodegenerative diseases.
Although OPTN levels were not significantly changed as shown by immunohistochemical analysis, total protein levels were reduced in spinal cord homogenates of microdissected anterior horn tissue from SALS cases when analysed by Western blot (Fig. 4) . There was no correlation of reduction of OPTN and b-3 tubulin (neuronal marker) ( Figure S4 ). However, b-3 tubulin is specific for a neuronal population other than motor neurons. It is unknown why OPTN is reduced in spinal cord of SALS patients; however, may be due to motor neuron loss. Reduced levels of OPTN on Western blot correlated with decrease of neuronal population in the brain ( Figure S4 ).
OPTN mutations have been associated with POAG [21] and linked to ALS [16] , but not FTLD [23] . The cellular function of OPTN, however, in health and disease is still largely unknown. Endogenous OPTN has a diffuse cytoplasmic distribution and localises partially to the Golgi but it is not a membrane protein [32] . OPTN is prone to oligomerisation and aggregation when mutant or overexpressed in cells [32] . It also forms complexes with transcription factors Rab8 [6] , huntingtin [9] and myosin VI [25] which are involved in membrane trafficking of proteins [10, 25, 31] as is OPTN [7, 25] . Overexpression and POAG-related mutation (E50K) of OPTN impair protein trafficking [20] , and defective protein trafficking may be a pathomechanism also contributing to ALS with OPTN mutation. However, OPTN levels are influenced by several factors including proinflammatory cytokine levels [29] , which are upregulated in ALS [17] .
OPTN has a polyubiquitin binding region [33] which confirms the observation that the inclusions in FALS and SALS with OPTN mutation are also ubiquitinated [16] . We detected OPTN aggregates and inclusions in both SALS and FTLD-TDP cases similar to those described in the heterozygous FALS with OPTN mutation case [16] . The homozygous OPTN deletion and truncation mutations are expected to cause a complete loss of OPTN protein and motor neuron degeneration. How this relates to OPTN deposition in cases without OPTN mutation remains to be elucidated. It is possible that the changes in OPTN expression and the formation of inclusions in SALS and FTLD are secondary effects and that OPTN may not play a major role in the pathogenesis of neurodegenerative diseases, including primary TDP-43 proteinopathies.
In a comprehensive immuno-histological survey we have shown that OPTN-positive inclusions are relatively rare, occurring in a minority of TDP-43 positive ALS, FTLD-TDP and FTLD-TDP with ALS cases and are absent in a range of other neurodegenerative diseases. Further research is required into the biological function of OPTN; however, current evidence does not support the proposition that OPTN deposition plays a central role in neurodegeneration.
